BiotechNews’ Post

Turning discovery into impact takes more than strong science. At a recent session at Cincinnati Children's with Chiesi Group, David Lough, PhD shared what industry looks for in early-stage innovation and academic partnerships. The takeaway: it is not just the idea. It is how well it is positioned for translation. Read more: https://lnkd.in/eMh9eTYX #Biotech #MedTech #TranslationalResearch #Innovation #LifeSciences #DigitalHealth #RareDisease

Our CEO Chris Hollowood has been on BioCentury Inc. TV to describe how unbiased approaches to target ID are an important guide in investment decision making at Syncona Limited and Slingshot Therapeutics

How do we find better drug targets and improve the chances of success in development?   In a recent conversation on The BioCentury Inc. Show, our CEO Chris Hollowood shared his perspectives on a key shift underway in biopharma.   Historically, target discovery has often been shaped by predefined hypotheses, with experiments designed to validate what researchers already believe to be true. The challenge with this approach is that it can limit how confidently we establish true causality.   Today, advances in tools and data are changing that. As Chris explains in this clip, more holistic and unbiased experiments allow scientists to explore biological systems at scale, covering far more ground and increasing the likelihood of identifying the best targets rather than those that simply appear to work.   This matters because stronger experimental design does not just improve discovery, it has the potential to reduce risk across the entire drug development process.   For Syncona, this changes how we evaluate new opportunities. We prioritise science grounded in robust evidence and build companies with a clear path to the clinic, enabling us to focus capital on programmes with a higher probability of success and meaningful patient impact.   Watch the full interview here: https://lnkd.in/g2HNsKUC   #Biotech #LifeSciences #HealthcareInnovation

𝗘𝘅𝗰𝗶𝘁𝗲𝗱 𝘁𝗼 𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗲 𝗢𝘂𝗿 𝗘𝘀𝘁𝗲𝗲𝗺𝗲𝗱 𝗣𝗮𝗻𝗲𝗹𝗶𝘀𝘁 - Suraj Nair We are pleased to welcome Suraj Nair to our upcoming Healthcare Series panel discussion. With experience at the intersection of deep science, biotechnology, and healthcare innovation, Suraj brings a valuable perspective on how scientific breakthroughs are evolving into scalable business and investment opportunities. As healthcare and biotech continue to advance rapidly, conversations around deep science investments, commercialization, innovation scalability, and long-term value creation are becoming increasingly important for investors, founders, and healthcare leaders alike. We look forward to an engaging discussion around biotechnology investments, healthcare innovation, strategic capital, and the future of scientific advancement in healthcare. If you are part of healthcare, biotech, pharma, medtech, investments, or innovation strategy this is a conversation worth being part of. 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗛𝗲𝗿𝗲: https://lnkd.in/gScg4yS3 #HealthcareInvestment #Biotech #DeepScience #HealthcareInnovation #LifeSciences #HealthcareLeadership #StrategicInvestments #Biotechnology #HealthcareStrategy #MedTech #HealthcareBusiness #ScientificInnovation #HealthcareTransformation #FutureOfHealthcare #OctavusConsulting

BIO 2026 is a chance to reconnect with the "why" behind biotech: improving lives.  Heading the world’s largest biotech gathering, the BIO International Convention, in San Diego (June 22–25)? Let’s connect you with Nishit Bhuva, Client Service Partner at a-connect.    Nishit partners with biotech and biopharma teams to tackle complex, science-driven challenges across the life sciences value chain, bringing together deep scientific understanding with commercial and strategic execution. He’s especially focused on:  ➡️ Patient-centric innovation and outcomes  ➡️ Launch, lifecycle, and go-to-market strategy  ➡️ Cross-functional alignment across commercial, medical, and access  ➡️ Turning complex data into decisions Up for a no-noise, high-value exchange? Connect with Nishit to share perspectives and tackle your biggest priorities.    #Biotechnology #CommercialExcellence #LifeSciences 

#BBI #Insights continues to explore how life sciences #innovation moves beyond scientific discovery and into real-world impact. In our latest reflection, we ask a central question: When does scientific discovery become an investable opportunity? Turning strong science into #real-#world value requires more than innovation alone. It demands strategic clarity, translational thinking, deep market understanding, and the ability to align scientific potential with the realities of execution and #long-#term #investment. Read more: https://lnkd.in/eXmpEgu8 Through BBI Insights, we aim to foster dialogue around the challenges and opportunities shaping the future of #LifeSciences and #healthcare #innovation. Contribution: Mark Treherne, Chris Howie. #BBICambridge #BBIInsights #LifeSciences #Biotech #HealthcareInnovation #InnovationStrategy #VentureCreation

CORDIS is proud to announce the publication of a new Results Pack on Health biotechnology. Featuring 10 EU-funded projects, the pack showcases advances across key areas including regenerative medicine, precision therapies, AI-enabled diagnostics and advanced manufacturing. Together, these projects reflect the breadth of Europe’s health biotech ecosystem and its potential to transform patient care. From improving access to innovative treatments to enabling more personalised and effective therapies, the results demonstrate the value of sustained investment in collaborative research. Get a glimpse of Europe’s future in healthcare. 👉 https://lnkd.in/eng2B-_S #Biotechnology #BioTech

𝐅��𝐨𝐦 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐀𝐫𝐞𝐚𝐬 𝐭𝐨 𝐏𝐨𝐫𝐭𝐟𝐨𝐥𝐢𝐨 𝐑𝐨𝐥𝐞𝐬 After finishing my recent series on autoimmune portfolio strategy, I came across “𝐬𝐡𝐢𝐟𝐭𝐬 𝐢𝐧 𝐩𝐡𝐚𝐫𝐦𝐚’𝐬 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐚𝐫𝐞𝐚 𝐟𝐨𝐜𝐮𝐬”, a paper by teams at McKinsey & Company published in Nature Reviews Drug Discovery. What I found most useful was not the headline that capital is moving. It was the framework underneath it. The paper describes a mix of visible “loud” shifts and more gradual “silent” shifts in pharma R&D allocation. But the more interesting point is that these moves increasingly look less like simple therapeutic-area rotation and more like 𝐩𝐨𝐫𝐭𝐟𝐨𝐥𝐢𝐨 𝐝𝐞𝐬𝐢𝐠𝐧. Large-population franchises create scale, cash flow, and operating leverage. Rare and precision-oriented programs create differentiation, biological depth, and long-term optionality. In other words, these are not interchangeable bets. They play different roles inside the same portfolio. A strong portfolio is not built by choosing one type of biology over another. It is built by combining assets that do different strategic jobs: 👉 some create breadth and scale, 👉 others create certainty, differentiation, and durability. So the more interesting strategic question may not be: 𝐖𝐡𝐢𝐜𝐡 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐚𝐫𝐞𝐚 𝐢𝐬 𝐚𝐭𝐭𝐫𝐚𝐜𝐭𝐢𝐧𝐠 𝐚𝐭𝐭𝐞𝐧𝐭𝐢𝐨𝐧? It may be: 𝐖𝐡𝐢𝐜𝐡 𝐩𝐨𝐫𝐭𝐟𝐨𝐥𝐢𝐨 𝐫𝐨𝐥𝐞𝐬 𝐚𝐫𝐞 𝐛𝐞𝐜𝐨𝐦𝐢𝐧𝐠 𝐦𝐨𝐫𝐞 𝐯𝐚𝐥𝐮𝐚𝐛𝐥𝐞; 𝐚𝐧𝐝 𝐰𝐡𝐞𝐫𝐞 𝐝𝐨𝐞𝐬 𝐭𝐡𝐞 𝐛𝐢𝐨𝐥𝐨𝐠𝐲 𝐣𝐮𝐬𝐭𝐢𝐟𝐲 𝐞𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧? Curious how others think about this, especially when translating mechanism-level insight into portfolio design. #DrugDevelopment #PortfolioStrategy #PharmaStrategy #Immunology #RAndDStrategy #Biotech #LifeSciences

Thank you AusBiotech for publishing our article on Care and Compliance in Femtech Software. With apps and devices gathering private health data and offering medical insights, the distinction between lifestyle tools and regulated medical technologies can become blurred. Together with Naomi Omundson and Melissa Miller, we appreciate the opportunity to highlight the Australian regulatory framework.

I’m looking forward to AusMedtech 2026 by AusBiotech in Perth next week and hearing the conversations shaping the future of Australia’s medtech sector. For those also attending, I’d encourage you to read the latest edition of Australasian Biotechnology. It provides a useful preview of some of the topics likely to be discussed across innovation, commercialisation, manufacturing and the broader sector, including a feature from Cook, page 46 #AusMedtech2026 #medtech